Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Table 4 Univariate and multivariate analyses of the prognostic factors for progression-free survival

Factors	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
AFP (≤ 1210 vs > 1210), ng/mL	1.11 (0.71-1.74)	0.642	-	-
Age (≥ 60 vs < 60), years	1.68 (1.09-2.60)	0.019	1.13 (0.70-1.83)	0.624
Alcohol (yes vs no)	0.94 (0.60-1.46)	0.784	-	-
ALT (> 40 vs ≤ 40), U/L	0.86 (0.56-1.30)	0.468	-	-
BCLC stage (C vs B)	1.85 (1.17-2.93)	0.008	2.60 (1.56-4.33)	< 0.001
BMI (normal vs overweight/obesity)	0.28 (0.15-0.52)	< 0.001	0.32 (0.17-0.59)	< 0.001
Child-Pugh score (B vs C)	2.71 (1.73-4.23)	< 0.001	2.30 (1.44-3.67)	< 0.001
Diabetes (yes vs no)	0.88 (0.53-1.49)	0.644	-	-
Cirrhosis (yes vs no)	0.98 (0.64-1.49)	0.922	-	-
ECOG (2 vs 0-1)	2.37 (1.50-3.72)	< 0.001	2.22 (1.37-3.61)	0.001
HBe (positive vs negative)	1.29 (0.82-2.03)	0.273	-	-
HBV-DNA (HBV ≤ 2000 vs HBV > 2000), IU/mL	1.27 (0.83-1.95)	0.276	-	-
Hypertensive (yes vs no)	1.10 (0.68-1.78)	0.709	-	-
PVTT (yes vs no)	1.06 (0.66-1.67)	0.820	-	-
Metastasis (yes vs no)	0.81 (0.53-1.23)	0.321	-	-
Sex (male vs female)	0.89 (0.58-1.35)	0.576	-	-
Smoking (yes vs no)	1.02 (0.65-1.61)	0.919	-	-
Total bilirubin (≤ 34 vs > 34), μmol/L	0.30 (0.18-0.50)	< 0.001	0.38 (0.21-0.67)	0.001
Interventional (yes vs no)	0.77 (0.48-1.22)	0.263	-	-

HR: Hazard ratio; CI: Confidence interval; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; BMI: Body mass index; BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; HBV: Hepatitis B virus; PVTT: Portal vein tumor thrombosis.